Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Creatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 18/20 | 0.41 |
| ▸ | CA2 | P00918 | 18/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Creatine SCHEMBL7858043 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL4885845 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL3816605 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL6673726 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL5569335 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL675800 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL4269044 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL9391271 | 0.93 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL9568829 | 0.92 | NOS3 (0.39) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL1065566 | 0.88 | NOS3 (0.39) | CA1CA2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226947-B1 | Use of creatine as a fat substitute | ALZCHEM TROSTBERG GMBH (DE) | 2007-06-05 | — | — | US | claimed |
| EP-1176875-B1 | USE OF CREATINE AS A FEED SUBSTITUTE | DSM FINE CHEM AUSTRIA GMBH (AT) | 2005-01-19 | — | — | EP | claimed |
| EP-3307064-B1 | LONG TERM STORAGE AND PRESERVATION OF PLATELETS | HARVARD COLLEGE (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20190045776-A1 | LONG TERM STORAGE AND PRESERVATION OF PLATELETS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-02-14 | — | — | US | disclosed |
| EP-3307064-A1 | LONG TERM STORAGE AND PRESERVATION OF PLATELETS | President and Fellows of Harvard College (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016201121-A1 | LONG TERM STORAGE AND PRESERVATION OF PLATELETS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-12-15 | — | — | WO | disclosed |
| US-7511164-B2 | Enhanced bioavailability; reacting creatine, fatty acid and thionyl halide | MULTI FORMULATIONS LTD (CA) | 2009-03-31 | — | — | US | disclosed |
| WO-2008101309-A1 | CREATINE-FATTY ACIDS | MULTI FORMULATIONS LTD. (CA) | 2008-08-28 | — | — | WO | disclosed |
| US-20080200723-A1 | CREATINE-FATTY ACIDS | MULTI FORMULATIONS LTD. (CA) | 2008-08-21 | — | — | US | disclosed |
| US-7314945-B1 | Creatine-fatty acids | MULTI FORMULATIONS LTD. (CA) | 2008-01-01 | — | — | US | disclosed |
| US-7226947-B1 | Use of creatine as a fat substitute | ALZCHEM TROSTBERG GMBH (DE) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200723-A1 | CREATINE-FATTY ACIDS | FABP2, FABP3, FABP1 | CA1 742/4885CA2 349/4885NOS3 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.